

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Fatty acid synthase (FASN; FAS)	<p><i>In vitro</i> and mouse studies suggest that inhibiting FASN could help treat prostate cancer. In human prostate cancer cells, overexpression of FASN increased cellular proliferation. Small interfering RNA inhibition of <i>FASN</i> in the cells induced apoptosis. Next steps include developing small molecule FASN inhibitors.</p> <p>FASgen Inc. has FASN inhibitors, including FAS93 and FAS31, in preclinical testing to treat ovarian and non-small cell lung cancer (NSCLC).</p> <p>SciBX 2(13); doi:10.1038/scibx.2009.531 Published online April 2, 2009</p>	Findings unpatented; cell lines and antibodies available for licensing soon	<p>Migita, T. <i>et al. J. Natl. Cancer Inst.</i>; published online March 24, 2009; doi:10.1093/jnci/djp030</p> <p>Contact: Massimo Loda, Dana-Farber Cancer Institute, Boston, Mass. e-mail: massimo_loda@dfci.harvard.edu</p>